How many clinical trials are there for Primary Peritoneal Cavity Cancer?

PlainTrial tracks 23 US clinical trials for Primary Peritoneal Cavity Cancer, of which 3 are currently recruiting.

Which interventions appear most often on Primary Peritoneal Cavity Cancer trial records?

topotecan hydrochloride is the most-linked intervention name on Primary Peritoneal Cavity Cancer records (3 trial links), followed by paclitaxel. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Primary Peritoneal Cavity Cancer?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt

Primary Peritoneal Cavity Cancer: early-phase trial registry

Compiled by PlainTrial · August 8, 2026

3 of 23 indexed Primary Peritoneal Cavity Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #724 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

23 US clinical trials · 3 currently recruiting · #724 of 28,707 conditions by registered trial count

Primary Peritoneal Cavity Cancer: 23 US clinical trials tracked, 3 recruiting.

Primary Peritoneal Cavity Cancer is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.

Enrollment posture brief

Registry condition primary-peritoneal-cavity-cancer

Volume-matched condition peers

Nearest open-share peer: Chest Pain (13% recruiting · 23 trials)

Open-enrollment share among volume-matched conditions near Primary Peritoneal Cavity Cancer

Primary Peritoneal Cavity Cancer lists 3 open slots (13% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Peritoneal Cavity Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Primary Peritoneal Cavity Cancer is recruiting below its size-band peers.

3 of 23 indexed trials (13%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
One sponsor concentrates Primary Peritoneal Cavity Cancer research.

National Cancer Institute (NCI) accounts for 8 of 23 trials (34.8%). 9 distinct sponsors appear on at least one study for this condition label.
Most Primary Peritoneal Cavity Cancer trials plan to enrol fewer than 100 people.

Median target enrolment is 35 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.
Primary Peritoneal Cavity Cancer research is mostly interventional.

23 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Open and recent trials

23 total, page 1 of 1

RECRUITING Phase 1 319 participants

A Study of XMT-1660 in Participants With Solid Tumors

Mersana Therapeutics

NCT05377996

RECRUITING Phase 1 33 participants

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

NCT06342986

RECRUITING Phase 2 18 participants

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06617923

COMPLETED NA 375 participants

Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer

Wake Forest University Health Sciences

NCT01656044

COMPLETED Phase 3 324 participants

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Gynecologic Oncology Group

NCT00002717

COMPLETED Phase 2 136 participants

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Wake Forest University Health Sciences

NCT01580410

COMPLETED Phase 2 61 participants